The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.As a result, Crispen-based treatments meant to target age-related genomic changes are in development. Leading organizations are looking at methods to fix aging DNA, and businesses are using artificial intelligence to find molecules that either halt or slow down aging.These discoveries and more are enabling the FDA and ot ...